ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 14, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 14, 2011
News
FDA Publishes Guidance for Preventing Cross-Contamination
By Erik Greb
FDA recently published guidance for preventing the cross-contamination of finished pharmaceuticals and active pharmaceutical ingredients with nonpenicillin beta-lactam antibiotics.
Merck Forms Joint Venture with Sun Pharmaceutical
By Patricia Van Arnum
Merck & Co. has formed a joint venture with the Mumbai-based specialty pharmaceutical company Sun Pharmaceutical Industries to develop, manufacture, and commercialize new combinations and formulations of branded generic drugs in emerging markets.
J&J Announces Settlement for Corrupt Practices
By Stephanie Sutton
Johnson and Johnson (J&J) has agreed to pay more than $77 million after being charged for violations of the US Foreign Corrupt Practices Act, which include bribing public doctors in several European countries and paying kickbacks to illegally obtain business in Iraq.
A Record Number of Therapies for Cancer Currently in Development
By Amy Ritter
Nearly 900 therapies for the treatment, diagnosis or prevention of cancer are currently in development, according to a report released by PhRMA.
Regulatory Roundup: FDA Released Draft Guidance for Industry on Safety Labeling Changes
FDA Released Draft Guidance for Industry on Safety Labeling Changes.
Week of Apr. 14, 2011: Company and People Notes: Alynlyam forms drug-delivery pact with the University of British Columbia; Linda S. Mayer Joins Schott North America; and More.
Alynlyam forms drug-delivery pact with the University of British Columbia; Linda S. Mayer Joins Schott North America; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
100%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
0%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Click here